Prior to randomization patients with any non-hematologic toxicity from surgery, chemotherapy, or radiation must have recovered to grade =<  with the exception of alopecia and the criteria outlined
Prior to randomization patients with any non-hematologic toxicity from surgery, chemotherapy and radiation therapy must have recovered to grade =<  with the exception of alopecia, ototoxicity and neuropathy
Grade >=  non-hematologic toxicity from prior therapy that has not resolved to =< grade (G) 
Should be off any active therapy for AML with the exception of hydroxyurea for at least  days prior to study registration unless patient has rapidly progressive disease, and all grade - non-hematologic toxicities should have resolved
Grade >=  non-hematologic toxicity from previous therapy that has not resolved to =< grade (G)
Grade >=  non-hematologic toxicity from previous therapy that has not resolved to =< grade 
Patients must have recovered from acute non hematologic toxicity (to =< grade ) of all previous therapy prior to enrollment
Patients who have not recovered from acute non hematologic toxicity (to =< grade ) of all previous therapy prior to enrollment
Grade >=  non-hematologic toxicity from previous therapy that has not resolved to =< grade 
Has persistent, clinically significant > Grade  non-hematologic toxicity from prior AML therapies
Grade >=  non-hematologic toxicity from prior therapy that has not resolved to =< grade  (G).
Non-hematologic toxicities from previous cancer therapies resolved to =< grade 
Patients must have recovered from acute toxicities of prior chemotherapy or stem cell transplant; any prior non-hematologic vital organ toxicity (cardiac, pulmonary, hepatic, renal) of previous therapy must have resolved to grade  or less
All previous cytotoxic chemotherapy must be completed at least  weeks prior to study entry; any prior non-hematologic vital organ toxicity (cardiac, pulmonary, hepatic, renal) of any previous therapy must have resolved to grade  or less, unless specified elsewhere\r\n* Exceptions:\r\n** There is no time restriction in regard to prior intrathecal chemotherapy provided there is complete recovery from any acute toxic effects; or\r\n** Subjects receiving standard ALL maintenance chemotherapy will not require washout
All previous intravenous therapy administered outside of the National Institute of Health (NIH) Clinical Center must be completed at least  weeks prior to study entry, with recovery to =< non-hematologic grade  toxicity of previous therapy
Persistent, clinically significant > Grade  non-hematologic toxicity from prior AML therapy.
Patients must not have any known, persistent (>  weeks), ?Grade  hematologic toxicity during the last cancer therapy. Patients must not have any known, persistent (> weeks), ? Grade  fatigue during the last cancer therapy.
Failure to recover (to CTCAE Version . Grade  or Grade ) from acute non hematologic toxicity (except all grades of alopecia or Grade  or lower neuropathy), due to previous therapy, prior to Screening.
Known persistent (>  weeks) ? Grade  neutropenia, ? Grade  thrombocytopenia or > Grade  anemia from prior cancer therapy
Should be off any active systemic therapy for AML with the exception of hydroxyurea for at least  days prior to study registration unless patient has rapidly progressive disease, and all grade - non-hematologic toxicities should have resolved
Completed > % of the prescribed radiation therapy and concurrent temozolomide according to the Stupp regimen without grade  or  hematologic toxicity
Any grade  or  -hematologic toxicity of previous therapy must have resolved to grade  or less prior to apheresis and any grade  or  toxicity must have resolved to grade  or less prior to pre-infusion lymphodepletive chemotherapy.
All previous cytotoxic chemotherapy must be completed at least  weeks prior to study entry, with the exception of the tyrosine kinase inhibitors imatinib, nilotinib and dasatinib which may be continued through induction therapy; any grade  or  nonhematologic toxicity of any previous therapy must have resolved to grade  or less, unless specified elsewhere
Failure to recover to Grade  or Grade  from acute non-hematologic toxicity due to previous therapy, prior to screening (with the exception of alopecia).
Patients are permitted to have been treated with previous systemic chemotherapy; a minimal time interval since last dose of cytotoxic chemotherapy must be equal to or greater than  days, and all acute toxicities should be resolved to less than grade , and hematologic counts should meet study criteria; with regards to toxicity, patients who have left sided chest wall recurrences should not have previously exceeded more than  mg/m^ doxorubicin due to expected cumulative cardiotoxicity; prior taxane therapy is allowed, however, there should be no reported anaphylactic reactions of grade  or higher
Patients with grade >=  non-hematologic toxicity from previous therapy that has not resolved to =< grade 
Should be off any active therapy for AML with the exception of hydroxyurea for at least  days prior to study registration unless patient has rapidly progressive disease, and all grade - non-hematologic toxicities should have resolved
Patients with unresolved grade >  non-hematologic toxicity from previous therapy; patients with grade  toxicity will be eligible at the discretion of the Principal Investigator (PI)
All previous therapy must be completed at least  weeks prior to study entry; any grade  or  non-hematologic toxicity of any previous therapy must have resolved to grade  or less, unless specified elsewhere
Grade >=  non-hematologic toxicity from prior therapy that has not resolved to =< G
Any grade  or  hematologic toxicity of any previous therapy must have resolved to grade  or less prior to apheresis and any grade  or  toxicity must have resolved to grade  or less prior to pre-infusion lymphodepletive chemotherapy.
grade  hematologic toxicity lasting more than  days, or a documented inability to sustain the TKI therapy because of recurrent grade  or  hematologic toxicity with re-initiation of the same therapy
Failure to recover from acute non hematologic toxicity (except alopecia or Grade  or lower neuropathy), due to previous therapy, prior to Screening.